PrecigenSTU:I5X -1.64%59 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates STU:I5X with a GF Score™ of 59/100 and a GF Value™ of €5.33 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 376 Biotechnology companies, Precigen ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Precigen's
Operating Income
for the
three
months ended in Mar. 2026 was €-5.19 Mil. Precigen's Interest Expense for the
three
months ended in Mar. 2026 was €-2.52 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Precigen's Interest Coverage or its related term are showing as below:
STU:I5X's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 110.86 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Precigen Interest Coverage Related Terms
Precigen Interest Coverage Historical Data
* Premium members only.
The historical data trend for Precigen's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:I5X vs KARD, SLBT, GENB: Interest Coverage Comparison
For the Biotechnology subindustry, Precigen's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Precigen's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Precigen did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Precigen (STU:I5X) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Precigen and its competitors. According to the industry distribution chart, Precigen ranks #999999 out of 376 companies in the Biotechnology industry.
Is Precigen's Interest Coverage too high?
Precigen's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Precigen ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Precigen has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Interest Coverage compare to KARD and SLBT?
According to the Biotechnology industry distribution chart, Precigen ranks #999999 out of 376 companies for Interest Coverage. This places Precigen in the lower half of its industry. The industry median Interest Coverage is 110.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Precigen and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precigen's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.33, compared to a current price of €4.80 — trading 9.9% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Precigen's overall GF Score™ is 59/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Precigen (STU:I5X), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (STU:I5X) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be undervalued.
The current stock price of €4.80 is trading 9.9% below its estimated GF Value™ of €5.33.
GuruFocus considers Precigen to be Modestly Undervalued.
Key valuation signals for STU:I5X:
Interest Coverage: 0 (At Loss)
GF Value™: €5.33 vs. price of €4.80 (9.9% below fair value)
No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
59GF Score
Get the complete analysis for STU:I5X
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I5X has been successfully added to your 
